BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ng V, Saab S. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011;9:923-30. [PMID: 21699815 DOI: 10.1016/j.cgh.2011.05.028] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Tillmann HL. Hepatitis C virus infection: when is a cure not a cure? J Infect Dis 2014;209:6-8. [PMID: 24127562 DOI: 10.1093/infdis/jit543] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
2 Noureddin M, Anstee QM, Loomba R. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2016;43:1109-23. [PMID: 27061197 DOI: 10.1111/apt.13620] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
3 Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, Mathurin P, Tran A, Larrey DG, Ratziu V, Alric L, Hyland RH, Jiang D, Doehle B, Pang PS, Symonds WT, Subramanian GM, McHutchison JG, Marcellin P, Habersetzer F, Guyader D, Grangé JD, Loustaud-Ratti V, Serfaty L, Metivier S, Leroy V, Abergel A, Pol S. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015;15:397-404. [PMID: 25773757 DOI: 10.1016/S1473-3099(15)70050-2] [Cited by in Crossref: 219] [Cited by in F6Publishing: 88] [Article Influence: 31.3] [Reference Citation Analysis]
4 Kanaan N, Raggi C, Goffin E, De Meyer M, Mourad M, Jadoul M, Beguin C, Kabamba B, Borbath I, Pirson Y. Outcome of hepatitis B and C virus-associated hepatocellular carcinoma occurring after renal transplantation. J Viral Hepat. 2017;24:430-435. [PMID: 27917563 DOI: 10.1111/jvh.12655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Matsuda T, Mccombs JS, Tonnu-mihara I, Mcginnis J, Fox DS. The Impact of Delayed Hepatitis C Viral Load Suppression on Patient Risk: Historical Evidence from the Veterans Administration. Forum for Health Economics and Policy 2016;19:333-51. [DOI: 10.1515/fhep-2015-0041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Rizzetto M, Grotzinger K, Theodore D, Demuth D, Irving WL, Manns M, Roughley A, Forssen UM. Reasons for nonuse of antiviral treatment in patients with chronic hepatitis C infection and thrombocytopaenia: a retrospective chart review from five European countries. J Viral Hepat 2014;21:e129-34. [PMID: 24698004 DOI: 10.1111/jvh.12256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
7 Jung CH, Um SH, Kim TH, Yim SY, Suh SJ, Yim HJ, Seo YS, Choi HS, Chun HJ. Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C. Gut Liver 2016;10:808-17. [PMID: 27114417 DOI: 10.5009/gnl15360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
8 Saab S, Jackson C, Nieto J, Francois F. Hepatitis C in African Americans. Am J Gastroenterol 2014;109:1576-84; quiz 1575, 1585. [PMID: 25178700 DOI: 10.1038/ajg.2014.243] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
9 Giordanino C, Sacco M, Ceretto S, Smedile A, Ciancio A, Cariti G, De Blasi T, Picciotto A, Marenco S, Grasso A. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting. Eur J Gastroenterol Hepatol. 2013;Epub ahead of print. [PMID: 23719564 DOI: 10.1097/meg.0b013e328362dc99] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
10 Goel A, Bhargava R, Rai P, Aggarwal R. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience. Indian J Gastroenterol 2017;36:227-34. [PMID: 28656492 DOI: 10.1007/s12664-017-0763-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
11 Manne V, Akhtar E, Saab S. Cirrhosis regression in patients with viral hepatitis B and C: a systematic review. J Clin Gastroenterol. 2014;48:e76-e84. [PMID: 24921210 DOI: 10.1097/mcg.0000000000000162] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.9] [Reference Citation Analysis]
12 Gurusamy KS, Wilson E, Koretz RL, Allen VB, Davidson BR, Burroughs AK, Gluud C. Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention? PLoS One. 2013;8:e83313. [PMID: 24349487 DOI: 10.1371/journal.pone.0083313] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
13 Tseng KC, Ho YC, Tseng CW, Tseng LH, Hsieh YH, Chang TT, Wu SF. Decrease in regulatory T-cell function in chronic hepatitis C patients receiving pegylated-interferon plus ribavirin. Int J Infect Dis 2017;58:8-17. [PMID: 28238888 DOI: 10.1016/j.ijid.2017.02.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
14 Nuño Solinís R, Arratibel Ugarte P, Rojo A, Sanchez Gonzalez Y. Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. Infect Dis Ther 2016;5:491-508. [PMID: 27783223 DOI: 10.1007/s40121-016-0134-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
15 Backus LI, Belperio PS. Impact of sustained virologic response on all-cause mortality: Hepatology Elsewhere. Hepatology 2013;58:1508-10. [DOI: 10.1002/hep.26504] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
16 Wong WW, Haines A, Farhang Zangneh H, Shah H. Can we afford not to screen and treat hepatitis C virus infection in Canada? CanLivJ 2018;1:51-65. [DOI: 10.3138/canlivj.1.2.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Cabalak M, Bal T, Onlen Y, Demir M. Incidence and predictors of direct-acting antiviral treatment failure in Turkish patients with chronic hepatitis C genotype 1b infection. Trop Doct 2020;50:141-6. [PMID: 31810415 DOI: 10.1177/0049475519892082] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Par G, Szereday L, Berki T, Palinkas L, Halasz M, Miseta A, Hegedus G, Szekeres-Bartho J, Vincze A, Hunyady B, Par A. Increased baseline proinflammatory cytokine production in chronic hepatitis C patients with rapid virological response to peginterferon plus ribavirin. PLoS One 2013;8:e67770. [PMID: 23874444 DOI: 10.1371/journal.pone.0067770] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
19 Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis. 2015;15:19. [PMID: 25596623 DOI: 10.1186/s12879-015-0748-8] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 15.0] [Reference Citation Analysis]
20 Edlin BR. Hepatitis C screening: getting it right. Hepatology 2013;57:1644-50. [PMID: 23239521 DOI: 10.1002/hep.26194] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
21 Cornella SL, Stine JG, Kelly V, Caldwell SH, Shah NL. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series. Postgrad Med. 2015;127:413-417. [PMID: 25746436 DOI: 10.1080/00325481.2015.1021660] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 7.4] [Reference Citation Analysis]
22 Duddempudi AT, Bernstein DE. Hepatitis B and C. Clinics in Geriatric Medicine 2014;30:149-67. [DOI: 10.1016/j.cger.2013.10.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
23 Prenner S, Kulik L. HCC: Where Does HCV Therapy Play a Role? Curr Hepatology Rep 2016;15:17-25. [DOI: 10.1007/s11901-016-0292-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
24 Vinaixa C, Strasser SI, Berenguer M. Disease Reversibility in Patients With Post-Hepatitis C Cirrhosis: Is the Point of No Return the Same Before and After Liver Transplantation? A Review. Transplantation. 2017;101:916-923. [PMID: 28060241 DOI: 10.1097/tp.0000000000001633] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 2.6] [Reference Citation Analysis]
25 Afdhal NH, Dusheiko GM, Giannini EG, Chen P, Han K, Mohsin A, Rodriguez–torres M, Rugina S, Bakulin I, Lawitz E, Shiffman ML, Tayyab G, Poordad F, Kamel YM, Brainsky A, Geib J, Vasey SY, Patwardhan R, Campbell FM, Theodore D. Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy. Gastroenterology 2014;146:442-452.e1. [DOI: 10.1053/j.gastro.2013.10.012] [Cited by in Crossref: 88] [Cited by in F6Publishing: 76] [Article Influence: 11.0] [Reference Citation Analysis]
26 Singer AW, Reddy KR, Telep LE, Osinusi AO, Brainard DM, Buti M, Chokkalingam AP. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther. 2018;47:1278-1287. [PMID: 29516535 DOI: 10.1111/apt.14593] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
27 Nguyen NH, Nguyen MH. Current Treatment Options in Patients with Hepatitis C Virus Genotype 6. Gastroenterol Clin North Am 2015;44:871-81. [PMID: 26600225 DOI: 10.1016/j.gtc.2015.07.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
28 Lim EJ, Torresi J. Prevention of Hepatitis C Virus Infection and Liver Cancer. Recent Results Cancer Res 2021;217:107-40. [PMID: 33200364 DOI: 10.1007/978-3-030-57362-1_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Teriaky A, Reau N. Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era. Clin Liver Dis 2015;19:591-604, v. [PMID: 26466649 DOI: 10.1016/j.cld.2015.06.001] [Reference Citation Analysis]
30 Lam BP, Jeffers T, Younoszai Z, Fazel Y, Younossi ZM. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol 2015;8:298-312. [PMID: 26327920 DOI: 10.1177/1756283X15587481] [Cited by in Crossref: 73] [Cited by in F6Publishing: 23] [Article Influence: 10.4] [Reference Citation Analysis]
31 Yang YH, Chen WC, Tsan YT, Chen MJ, Shih WT, Tsai YH, Chen PC. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J Hepatol. 2015;63:1111-1117. [PMID: 26196278 DOI: 10.1016/j.jhep.2015.07.006] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 7.7] [Reference Citation Analysis]
32 Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, Wang H, Hu B, Coakley EP, Podsadecki TJ. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63:20-29. [PMID: 25646891 DOI: 10.1016/j.jhep.2015.01.026] [Cited by in Crossref: 96] [Cited by in F6Publishing: 91] [Article Influence: 13.7] [Reference Citation Analysis]
33 Nguyen LH, Nguyen MH. Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther. 2013;37:921-936. [PMID: 23557103 DOI: 10.1111/apt.12300] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 9.9] [Reference Citation Analysis]
34 Hussein HA, Allam AS, Moaty ASA. Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir. Curr Diabetes Rev 2020;16:165-70. [PMID: 31146663 DOI: 10.2174/1573399815666190531091128] [Reference Citation Analysis]
35 Ridruejo E. Increased mortality in chronic HCV infection. Annals of Hepatology 2012;11:967-8. [DOI: 10.1016/s1665-2681(19)31429-2] [Reference Citation Analysis]
36 Assoumou SA, Huang W, Young K, Horsburgh CR, Linas BP. Real-world Outcomes of Hepatitis C Treatment during the Interferon-free Era at an Urban Safety-net Hospital. J Health Care Poor Underserved 2017;28:1333-44. [PMID: 29176099 DOI: 10.1353/hpu.2017.0118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Xu F, Moorman AC, Tong X, Gordon SC, Rupp LB, Lu M, Teshale EH, Spradling PR, Boscarino JA, Trinacty CM, Schmidt MA, Holmberg SD; Chronic Hepatitis Cohort Study (CHeCS) Investigators, Holmberg SD, Teshale EH, Spradling PR, Moorman AC, Xing J, Tong X, Xu F, Gordon SC, Nerenz DR, Lu M, Lamerato L, Wang Y, Rupp LB, Akkerman N, Oja-Tebbe N, Zhang T, Li J, Sitarik A, Larkin D, Boscarino JA, Daar ZS, Curry PJ, Smith RE, Vijayadeva V, Parker JV, Schmidt MA, Donald JL, Keast EM. All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus. Clin Infect Dis. 2016;62:289-297. [PMID: 26417034 DOI: 10.1093/cid/civ860] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
38 Mcdermott CL, Lockhart CM, Devine B. Outpatient directly observed therapy for hepatitis C among people who use drugs: a systematic review and meta-analysis. Journal of Virus Eradication 2018;4:118-22. [DOI: 10.1016/s2055-6640(20)30255-7] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
39 Garg G, Dixit VK, Shukla SK, Singh SK, Sachan S, Tiwari A, Yadav VK, Yadav DP. Impact of Direct Acting Antiviral Drugs in Treatment Naïve HCV Cirrhosis on Fibrosis and Severity of Liver Disease: A Real Life Experience from a Tertiary Care Center of North India. J Clin Exp Hepatol 2018;8:241-9. [PMID: 30302040 DOI: 10.1016/j.jceh.2017.11.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
40 Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, Kahn JG. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med 2016;176:65-73. [PMID: 26595724 DOI: 10.1001/jamainternmed.2015.6011] [Cited by in Crossref: 94] [Cited by in F6Publishing: 85] [Article Influence: 15.7] [Reference Citation Analysis]
41 Jothimani D, Chandy GM, Conjeevaram H. A new era in the treatment of chronic hepatitis C infection. Indian J Gastroenterol 2013;32:71-9. [PMID: 23054947 DOI: 10.1007/s12664-012-0254-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
42 Bonder A, Afdhal NH. Biopsy No More; Changing the Screening and Diagnostic Algorithm for Hepatitis C. Clinical Gastroenterology and Hepatology 2013;11:309-10. [DOI: 10.1016/j.cgh.2012.12.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
43 Hsu Y, Wu C, Lin J. Hepatitis C Virus Infection, Antiviral Therapy, and Risk of Hepatocellular Carcinoma. Seminars in Oncology 2015;42:329-38. [DOI: 10.1053/j.seminoncol.2014.12.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
44 Mattos AA, Marcon Pdos S, Araújo FS, Coral GP, Tovo CV. HEPATOCELLULAR CARCINOMA IN A NON-CIRRHOTIC PATIENT WITH SUSTAINED VIROLOGICAL RESPONSE AFTER HEPATITIS C TREATMENT. Rev Inst Med Trop Sao Paulo 2015;57:519-22. [PMID: 27049708 DOI: 10.1590/S0036-46652015000600011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
45 Macaluso FS, Calvaruso V, Craxì A. Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye. Future Microbiol 2015;10:977-88. [PMID: 26059621 DOI: 10.2217/fmb.15.31] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
46 Tseng CW, Chang TT, Tzeng SJ, Hsieh YH, Hung TH, Huang HT, Wu SF, Tseng KC. Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C. Clin Interv Aging 2016;11:327-34. [PMID: 27051280 DOI: 10.2147/CIA.S97242] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Pan C, Chen Y, Chen W, Zhou G, Jin L, Zheng Y, Lin W, Pan Z. Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2016;1008:255-9. [PMID: 26684720 DOI: 10.1016/j.jchromb.2015.11.056] [Cited by in Crossref: 55] [Cited by in F6Publishing: 43] [Article Influence: 7.9] [Reference Citation Analysis]